[Targeting KRAS pathway in NSCLC therapy].
KRAS mutations are currently the most frequently mutated oncogenes in non-small cell lung cancers (NSCLC). A growing body of evidence suggests that targeting RAS could be an efficient strategy in NSCLC. Several approaches have been developed to target either RAS protein or downstream effectors such as RAF or MEK. First clinical trials evaluating farnesyltransferases inhibitors have led to unsuccessful results. However, targeting RAF and MEK could be a more efficient approach in NSCLC.
Le Moulec
S
S
Institut Gustave-Roussy, 39 bis, rue Camille-Desmoulins, 94800 Villejuif, France.
Loriot
Y
Y
Soria
J-C
JC
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001557:Benzenesulfonates / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics*; D051231:Farnesyltranstransferase / Q000037:antagonists & inhibitors; D011905:Genes, ras / Q000235:genetics*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D051379:Mice; D020929:Mitogen-Activated Protein Kinase Kinases / Q000037:antagonists & inhibitors / Q000502:physiology; D009154:Mutation / Q000235:genetics; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors / Q000502:physiology; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D010880:Piperidines / Q000627:therapeutic use; D011725:Pyridines / Q000627:therapeutic use; D015363:Quinolones / Q000627:therapeutic use; D000077157:Sorafenib; D048490:raf Kinases / Q000037:antagonists & inhibitors; D018631:ras Proteins / Q000037:antagonists & inhibitors / Q000502:physiology; D003986:Dibenzocycloheptenes
D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D051231:Farnesyltranstransferase; D020929:Mitogen-Activated Protein Kinase Kinases; D009363:Neoplasm Proteins; D009536:Niacinamide; D010671:Phenylurea Compounds; D010880:Piperidines; D011725:Pyridines; D015363:Quinolones; D000077157:Sorafenib; D048490:raf Kinases; D018631:ras Proteins; C115354:lonafarnib; D003986:Dibenzocycloheptenes; C402769:tipifarnib